| Clinical data | |
|---|---|
| Other names | ANEB-001; ANEB001; V-24343; V24343 |
| Drug class | Cannabinoid receptor antagonist; Cannabinoid CB1 receptor antagonist; Cannabinoid antidote |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H24ClF3N2O2 |
| Molar mass | 440.89 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Selonabant (INN, USAN; developmental code names ANEB-001, V-24343) is a cannabinoid CB1 receptor antagonist which is under development for the treatment of acute cannabinoid intoxication. It was also previously being developed to treat obesity, but development for this indication was discontinued. The drug is administered by intravenous infusion. It dramatically reduced the subjective effects of Δ9-tetrahydrocannabinol (THC) in a clinical trial. Selonabant is being developed by Vernalis and Anebulo Pharmaceuticals. As of December 2024, it is in phase 2 trials.